Sublimity Therapeutics

About:

Sublimity Therapeutics Limited (Sigmoid Pharma Limited), a specialty pharmaceutical company focused on the treatment of ulcerative colitis.

Website: http://www.sublimitytherapeutics.com/

Top Investors: OrbiMed, Longitude Capital, HBM Healthcare Investments, Pendopharm

Description:

Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.